Krish Patel has been appointed as the New Director of Lymphoma Research at SCRI

Sarah Cannon Research Institute (SCRI), a global leader in oncology research and community-based clinical trials, has announced the appointment of Krish Patel, MD, as Director of Lymphoma Research.

This strategic appointment will strengthen SCRI’s lymphoma clinical trial portfolio and further enhance its clinical research capabilities across nearly 250 locations. Dr. Patel will also serve as a medical oncologist at SCRI Oncology Partners in Nashville, Tennessee, beginning in mid-November.

Dr. Krish Patel, MD, was a clinical investigator, the Director of the Lymphoma Program, and the Director of Hematologic Malignancies and Cellular Therapy at the Swedish Cancer Institute (SCI) in Seattle, Washington. He was renowned for his expertise in the diagnosis, treatment, and management of lymphomas, chronic lymphocytic leukemia (CLL), and other hematologic malignancies. His work spanned both clinical care and cutting-edge research in the fields of immunotherapy, targeted therapy, and cellular therapies for blood cancers.

Dr. Patel earned his undergraduate and Doctor of Medicine degrees from Duke University, where he also completed his residency in Internal Medicine and his fellowship in Hematology/Oncology. During his time at Duke, he served as Chief Resident in Internal Medicine, showcasing his leadership abilities early in his career. His interest in research and clinical innovation led him to pursue a clinical research training fellowship at the National Institutes of Health (NIH), where he further honed his expertise in the development of novel therapies for hematologic cancers.

In his clinical practice, Dr. Patel specializes in the management of patients with lymphomas, CLL, and other hematologic malignancies, with a focus on personalized care and the integration of advanced therapies. He is recognized as an expert in cellular and non-cellular immunotherapies, including the use of CAR T-cell therapy, checkpoint inhibitors, and other novel immunomodulatory treatments. His clinical expertise is complemented by his deep commitment to advancing treatment options for these complex diseases through innovative research.

Dr. Patel’s research focuses on the early-stage development of novel targeted agents and immunotherapies, particularly in the context of lymphoid malignancies. As a principal investigator, he leads multiple therapeutic clinical trials at SCI, with a strong emphasis on phase I and II studies in lymphomas, CLL, and cellular therapies. His work aims to develop and refine treatments that can improve outcomes for patients with these challenging conditions, especially those who are refractory or resistant to standard therapies.

In addition to his clinical and research roles, Dr. Patel is an active member of the Paul G. Allen Research Center at SCI, where he serves as a steering committee member of the Center for Immuno-oncology. This affiliation allows him to collaborate with other experts in the field to drive forward novel immuno-oncology approaches and to integrate these innovations into clinical care. Through his leadership in research and patient care, Dr. Patel is committed to transforming the landscape of lymphoma and hematologic malignancy treatment, with the ultimate goal of improving patient outcomes and quality of life.

Dr. Patel’s contributions to the field have earned him recognition as a thought leader in the lymphoma and hematology oncology communities. His research, clinical trials, and commitment to patient care continue to push the boundaries of what is possible in the treatment of blood cancers, offering hope for new, more effective therapies for patients around the world.

About Sarah Cannon Research Institute (SCRI)

Sarah Cannon Research Institute (SCRI) is a globally recognized leader in oncology research, specializing in conducting community-based clinical trials to advance cancer therapies. Over the past three decades, SCRI has played a pivotal role in drug development, contributing to groundbreaking research that has helped bring many of today’s FDA-approved cancer treatments to market. The institute has conducted more than 750 first-in-human clinical trials and continues to be at the forefront of cancer research.

SCRI operates an extensive research network, bringing together over 1,300 physicians who are actively enrolling patients in clinical trials at more than 250 locations across 24 states in the U.S. This broad network ensures that patients across the country have access to cutting-edge clinical trials, offering them the opportunity to participate in studies that may lead to new, life-saving treatments.

Through its commitment to advancing cancer care, SCRI focuses on a wide range of research areas, including early-phase clinical trials, innovative therapies, and personalized medicine, with an emphasis on improving outcomes for patients facing various types of cancer. By collaborating with pharmaceutical companies, academic institutions, and other key players in the oncology field, SCRI continues to contribute to the development of novel therapies that can transform cancer treatment and improve patients’ lives.

For more information, visit oncodaily.com.